Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
5 pending office actions • 4 clients • 5 examiners • 4 art units • 0 of 5 (0%) have an AI response strategy ready
Singleton Law, PLLC has managed 162 career applications, primarily in the Biotechnology & Pharmaceuticals technology area. The firm has achieved a resolved allowance rate pct of 92.45. Currently, there are 4 pending office actions in its docket. The 162 career applications reflect the firm's specialized experience in the biotechnology sector.
The average office actions per allowance for this profile is 4.35. This metric indicates that applications in the Biotechnology & Pharmaceuticals field often require extensive prosecution to reach an allowance. The 92.45 resolved allowance rate pct is an indicator of success for the 162 career applications managed by the firm. With only 4 pending office actions, the firm's current active workload is focused. These data points provide a concise summary of the firm's performance and its focus on biotechnology and pharmaceutical technology.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 5 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARVICH, MARIA | 1 | 54.9% | +28.1% |
| SCOTLAND, REBECCA LYNN | 1 | 0.0% | +0.0% |
| BOWERS, ERIN M | 1 | 54.7% | +10.6% |
| QIAN, CELINE X | 1 | 47.6% | +16.9% |
| WOZNICKI, JACQUELINE | 1 | 49.8% | +26.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17765661 | Direct Cardiac Compression Device with Improved Durability | WOZNICKI, JACQUELINE | 14d |
| 18883789 | METHOD TO INCREASE DRUG SUBSTANCE YIELD | BOWERS, ERIN M | 46d |
| 19361525 | Unique Interferon Alpha 2B And New Method Of Making Thereof | MARVICH, MARIA | — |
| 18960416 | CANNABIS EXTRACT COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY FOR SKIN CARE | SCOTLAND, REBECCA LYNN | — |
| 18555503 | INHIBITORY RNA FOR THE CONTROL OF PHYTOPATHOGENS | QIAN, CELINE X | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17765661 | Direct Cardiac Compression Device with Improved Durability | WOZNICKI, JACQUELINE | 14d |
| 18883789 | METHOD TO INCREASE DRUG SUBSTANCE YIELD | BOWERS, ERIN M | 46d |
| 19361525 | Unique Interferon Alpha 2B And New Method Of Making Thereof | MARVICH, MARIA | — |
| 18555503 | INHIBITORY RNA FOR THE CONTROL OF PHYTOPATHOGENS | QIAN, CELINE X | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Pharmaessentia Corporation | 2 |
| Regenerex Pharma, Inc. | 1 |
| University of California | 1 |
| CORINNOVA INCORPORATED | 1 |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| 1653 | 1 |
| 1663 | 1 |
| 3774 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19361525 | Unique Interferon Alpha 2B And New Method Of Making Thereof | Pharmaessentia Corporation | MARVICH, MARIA | 1634 | §102§112 | Non-Final OA | — | Pending | Oct 17, 2025 |
| 18960416 | CANNABIS EXTRACT COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY FOR SKIN CARE | Regenerex Pharma, Inc. | SCOTLAND, REBECCA LYNN | §102§103§112Other | Non-Final OA | — | Pending | Nov 26, 2024 | |
| 18883789 | METHOD TO INCREASE DRUG SUBSTANCE YIELD | Pharmaessentia Corporation | BOWERS, ERIN M | 1653 | §103§112 | Final Rejection | 46d | Pending | Sep 12, 2024 |
| 18555503 | INHIBITORY RNA FOR THE CONTROL OF PHYTOPATHOGENS | The Regents of the University of California | QIAN, CELINE X | 1663 | §102§112 | Non-Final OA | — | Pending | Oct 13, 2023 |
| 17765661 | Direct Cardiac Compression Device with Improved Durability | Corinnova Incorporated | WOZNICKI, JACQUELINE | 3774 | §103§112 | Final Rejection | 14d | Pending | Mar 31, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial